Navigation Links
Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
Date:10/30/2007

n 2007 to be $1,400,000 per month and we believe our existing capital resources are adequate to fund our current plans for research and development activities well into 2009. Factors that will affect our anticipated monthly burn rate include, but are not limited to, the number of manufacturing runs required to supply our clinical trial program and the cost of each run, additional activities reducing our economic dependence on a single supplier, the number of clinical trials ultimately approved, the timing of patient enrollment in the approved clinical trials, the actual costs incurred to support each clinical trial, the number of treatments each patient will receive, the timing of the NCI's R&D activity, and the level of pre-clinical activity undertaken.

In the event that we choose to seek additional capital, we will look to fund additional capital requirements primarily through the issue of additional equity. We recognize the challenges and uncertainty inherent in the capital markets and the potential difficulties we might face in raising additional capital. Market prices and market demand for securities in biotechnology companies are volatile and there are no assurances that we will have the ability to raise funds when required.

Capital Expenditures

We spent $586,124 on intellectual property during the nine month period ending September 30, 2007 compared to $552,319 during the nine month period ending September 30, 2006. The change in intellectual property expenditures reflects the timing of filing costs associated with our expanded patent base. As well, we have benefited from a stronger Canadian dollar as our patent costs are typically incurred in U.S. currency. In the third quarter of 2007, two U.S. patents were issued bringing our total patents issued to 23 in the U.S. and six in Canada.

Investing Activities

Under our Investment Policy, we are permitted to invest in short-term instruments with a rating no less than R-1 (DBRS) with
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29

Related biology technology :

1. The state of global biotech: An Ernst & Young perspective
2. Olympics of biotechnology has international flavor
3. Biotech officials praise focus of new venture fund
4. Getting noticed in Genetown: Wisconsin biotech on display
5. Madison biotech NimbleGen files for IPO; one of states best-funded firms
6. Wisconsin biotech firm receives $107K NIH grant
7. Biotech executive books a career flight thats closer to home
8. Manufacturing partnership will move into biotech and biomedical spaces
9. Wisconsin wont get Georgia biotech without a fight
10. The 10 biggest events shaping biotech in 2006
11. Gala Biotech among companies sold for $3.3 billion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... 18, 2013 Edison ... firm, announces the initiation of full coverage ... company developing and marketing products for orphan ...      (Logo: http://photos.prnewswire.com/prnh/20130417/608168) Edison ... the investment merits of BioAlliance Pharma, focusing ...
(Date:6/18/2013)... The "Bioinformatics Market By Sector (Molecular Medicine, ... & Data Analysis Services) & Application (Genomics, Proteomics & Drug ... Drivers, Restraints, and Opportunities in North America ... and Rest of World. Browse ... 22 Figures 364 Pages and an ...
(Date:6/18/2013)... MINNEAPOLIS , June 18, 2013  Techne ... today that it has agreed to acquire 100% ... subsidiary Bionostics, Inc. (Bionostics).  Bionostics is a global ... control solutions that verify the proper operation of ... utilized in point of care blood glucose and ...
(Date:6/18/2013)... June 18, 2013 ... announced the addition of the report " ... " to their offering.      ... reviews basics of human genome variations, development ... large and small sequencers are described as ...
Breaking Biology Technology:Edison Expands French Healthcare Sector Coverage With Initiation of Coverage on BioAlliance Pharma 2Edison Expands French Healthcare Sector Coverage With Initiation of Coverage on BioAlliance Pharma 3Bioinformatics Market Worth $7.5 Billion by 2017 2Bioinformatics Market Worth $7.5 Billion by 2017 3Techne Corporation Announces Acquisition Agreement 2Techne Corporation Announces Acquisition Agreement 3Techne Corporation Announces Acquisition Agreement 4Techne Corporation Announces Acquisition Agreement 5DNA Sequencing: Technologies, Markets and Companies - 2013 Report 2
... lot of crap from the academic community for the theory ... Class. To summarize, Dr. Florida says that a citys predisposition ... , ,Some of Richs indexes are controversial. For example, ... the more likely the city is to be economically successful. ...
... assets to stimulate growth , ,MADISON - More than ... Tuesday to hear Madison Mayor Dave Cieslewiczs plan for the ... a model for a forward economy, a 38-page ... as a vision for how Madisons public and private sectors ...
... Inc. announced Thursday that its co-founder, Lance ... chairman in order to focus on the assessment and ... that John J. Puisis , Third Waves president ... and assume overall management of the company. , ,The ...
Cached Biology Technology:The Creative Class from my perspective 2Madisons visionary plan for a healthy economy 2Madisons visionary plan for a healthy economy 3
(Date:6/17/2013)... DETROIT On June 6, professors in Wayne ... only National Science Foundation-funded (NSF) Research Experience for ... undergraduates an opportunity to do cutting-edge research in ... , According to Alexey Petrov, Ph.D., professor of ... Arts, principal investigator and program director of the ...
(Date:6/17/2013)... foundations with more modern elements. Using this same approachbut ... Dietrich School of Arts and Sciences have designed a ... storage, and gas transport more efficient and at a ... issue of the Journal of the American Chemical ... builds upon Pitt Associate Professor of Chemistry Nathaniel Rosi,s ...
(Date:6/17/2013)... Vitamin D supplementation may help delay early onset of ... results were presented Monday at The Endocrine Society,s 95th ... generally begins between the ages of 10 and 14. ... 16 years of age. Precocious puberty is diagnosed in ... 8; in boys, it is diagnosed when these changes ...
Breaking Biology News(10 mins):Wayne State welcomes undergraduates from around the US for physics research experience 2'Chemical architects' build materials with potential applications in drug delivery and gas storage 2Vitamin D supplementation may delay precocious puberty in girls 2
... Fla. (Jan. 28, 2008) According to two studies ... No.10), stroke victims may benefit from human mesenchymal stem ... In both studies, the migration of chemically tagged transplanted ... which the transplanted cells reached damaged areas of the ...
... Bethesda, MD The Biophysical Society has announced the speakers ... Meeting of the Biophysical Society and the International Biophysics ... The new and notable symposium highlights the latest ... nominated and selected by the Societys program committee. ...
... is being so changed by humans that it is now ... a new worldwide overview by Duke University soil scientist Daniel ... Earth now being cultivated for food crops, grazed, or periodically ... a major scientific and policy issue, Richter said. His paper ...
Cached Biology News:Stroke victims may benefit from stem cell transplants 2Biophysical Society announces new and notable symposium speakers 2Earth's soils bear unmistakable footprints of humans 2
... Cap 0 (or Cap 0-like) RNA into ... has been shown to increase in vivo ... improvement is seen in Cap 0 structures ... as well as those Cap 0 structures ...
Form: Concentrated Applications: ELISA...
Form: Ready to use Applications: ELISA...
RABBIT ANTI HALOPERIDOL...
Biology Products: